Pa­tient foun­da­tion ac­cus­es rare dis­ease com­pa­ny Taysha of vi­o­lat­ing li­cens­ing agree­ment

A pa­tient group this sum­mer ac­cused Taysha Gene Ther­a­pies of breach­ing a con­tract to de­vel­op a ther­a­py for an ul­tra-rare con­di­tion, an­oth­er sign of deep ten­sions be­tween the com­pa­ny and fam­i­ly foun­da­tions.

In Ju­ly, Han­nah’s Hope Fund claimed that Taysha breached a li­cens­ing agree­ment that called for the com­pa­ny to de­vel­op a ther­a­py for gi­ant ax­on­al neu­ropa­thy, an ul­tra-rare con­di­tion that ren­ders pa­tients quad­ri­pleg­ic and is fol­lowed by ear­ly death, ac­cord­ing to an SEC fil­ing on Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER